Annexon (ANNX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Apr, 2026Executive summary
Annual meeting scheduled for June 11, 2026, via live webcast for shareholder participation.
Shareholders are encouraged to review proxy materials and vote online or virtually at the meeting.
Voting matters and shareholder proposals
Election of two Class III directors to serve until the 2029 annual meeting: Bettina M. Cockroft, M.D. and Douglas Love, Esq.
Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory vote to approve compensation of named executive officers.
Proposal to amend the Certificate of Incorporation to increase authorized common stock from 300,000,000 to 500,000,000 shares.
Proxies may vote on other business as may properly come before the meeting.
Board of directors and corporate governance
Board recommends voting in favor of all proposals, including director nominees and compensation matters.
Latest events from Annexon
- Late-stage clinical milestones on track, with $44.1M net loss and cash runway into H2 2027.ANNX
Q1 20267 May 2026 - Vonoprument showed 73% risk reduction in vision loss for GA, with pivotal Phase 3 data due Q4 2026.ANNX
KOL event29 Apr 2026 - Late-stage C1q inhibitors show strong efficacy in GBS and GA, with pivotal data due in 2026.ANNX
Corporate presentation27 Apr 2026 - Shareholders will vote on director elections, auditor ratification, executive pay, and a stock increase.ANNX
Proxy filing27 Apr 2026 - Board recommends approval of all proposals, including share increase and executive compensation.ANNX
Proxy filing16 Apr 2026 - Pivotal data and regulatory filings in GBS, GA, and ANX1502 expected to drive major milestones in 2026.ANNX
25th Annual Needham Virtual Healthcare Conference15 Apr 2026 - Late-stage pipeline advances and strong cash position support multiple 2026 milestones.ANNX
Q4 202530 Mar 2026 - Late-stage neuroinflammatory pipeline poised for major clinical and commercial milestones.ANNX
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - ANX005 30 mg/kg met key efficacy and safety endpoints in GBS, advancing toward FDA submission.ANNX
Study Update31 Jan 2026